A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients

Archive ouverte

Hirschfield, Gideon, M | Chazouillères, Olivier | Cortez-Pinto, Helena | Macedo, Guilherme | de Lédinghen, Victor | Adekunle, Femi | Carbone, Marco

Edité par CCSD ; Taylor and Francis Group -

International audience. Introduction: Primary biliary cholangitis (PBC) is an infrequent, immune-mediated cholestatic liver disease, which can lead to liver fibrosis, cirrhosis and complications of end-stage liver disease. The established goals of treatment of PBC are prevention of end-stage liver disease and amelioration of associated symptoms. The European Association for the Study of the Liver (EASL) management guidelines provide extensive recommendations on the diagnosis and management of PBC.Areas covered: This article describes the development by expert consensus of a 'PBC Integrated Patient Care Pathway' to simplify and standardize the management of PBC for clinicians based on current practice.Expert opinion: Guideline adoption is potentially poor in practice since most patients with PBC in the community are seen by general gastroenterologists or hepatologists without a special interest in autoimmune liver disease. The PBC Integrated Patient Care Pathway is a best practice tool for clinicians designed to complement the EASL Clinical Practice Guidelines for the diagnosis and management of PBC patients. It gives clinicians a practical decision tree of the key steps in PBC management, thereby providing a simplified framework and an opportunity for more uniform practice that supports the safe and timely adoption of varied models of care provision to patients with PBC.

Suggestions

Du même auteur

Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis

Archive ouverte | Lemoinne, Sara | CCSD

International audience. Background & aims: Primary sclerosing cholangitis (PSC) has a variable, often progressive, course. Magnetic resonance cholangiography (MRC) is used in the diagnosis of PSC. Magnetic resonance...

A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA

Archive ouverte | Hirschfield, Gideon, M | CCSD

International audience. Placebo + 12-16 mg/kg UDCA N = 22 9 mg Budesonide + 12-16 mg/kg UDCA N = 40

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial

Archive ouverte | Hirschfield, Gideon, M | CCSD

International audience. BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an inflammatory, cholestatic and progressively fibrotic liver disease devoid of effective medical intervention. NGM282, an engineere...

Chargement des enrichissements...